Foundation Ipsen Template

We have over 25+ years of experience in neutrotoxins.

We are the only company with recombinant botulinum neutrotoxins in our portfolio. We have over 1000+ employees supporting neurosciences.

As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) made the company an attractive collaborator for Blueprint Medicines.
Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.

. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease.

. As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities.

Including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) – made the company an attractive collaborator for Blueprint Medicines.

In addition to acquiring Clementia and its FOP asset palovarotene, Ipsen had access to the strong relationships with all the patient organizations. Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.

We have over 25+ years of experience in neutrotoxins.

We are the only company with recombinant botulinum neutrotoxins in our portfolio. We have over 1000+ employees supporting neurosciences.

As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) made the company an attractive collaborator for Blueprint Medicines.
Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.

. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease.

. As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities.

Including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) – made the company an attractive collaborator for Blueprint Medicines.

In addition to acquiring Clementia and its FOP asset palovarotene, Ipsen had access to the strong relationships with all the patient organizations. Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.

We have over 25+ years of experience in neutrotoxins.

We are the only company with recombinant botulinum neutrotoxins in our portfolio. We have over 1000+ employees supporting neurosciences.

As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) made the company an attractive collaborator for Blueprint Medicines.
Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.

. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease.

. As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities.

Including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) – made the company an attractive collaborator for Blueprint Medicines.

In addition to acquiring Clementia and its FOP asset palovarotene, Ipsen had access to the strong relationships with all the patient organizations. Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.

MISSION

Accelerate rare disease diagnosis

There are 7,000 rare diseases affecting 300 million people worldwide. 75% of patients are children. 1 in 2 patients does not have an accurate diagnosis. A quarter of patients wait 4 years to get a diagnosis. Our program brings together world experts to improve this dire situation.

Know More

We changed how we screen companies and compounds, so we can make decisions faster and focus on the ones we want to push forward.

Chief Executive Ofiicer

We have over 25+ years of experience in neutrotoxins.

We are the only company with recombinant botulinum neutrotoxins in our portfolio. We have over 1000+ employees supporting neurosciences.

As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) made the company an attractive collaborator for Blueprint Medicines.
Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.

. Ipsen’s world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease.

. As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities.

Including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) – made the company an attractive collaborator for Blueprint Medicines.

In addition to acquiring Clementia and its FOP asset palovarotene, Ipsen had access to the strong relationships with all the patient organizations. Those relationships, a patient registry, and natural history data demonstrated Ipsen’s commitment to FOP and to bringing Blueprint’s FOP asset to market for those who eventually need it.